TuHURA Q2 2026: $1.0M Cash, $50M Credit Facility Draws, CEO 10b5-1 Plan
HURA has more than doubled off its 52-week low of $0.41.
Summary
TuHURA reported Q2 2026 results with $1.0 million in cash, a $9.2 million net loss, and reliance on a $50 million credit facility to extend runway into 2028. CEO James Bianco adopted a 10b5-1 plan for potential sales of up to 1.5 million shares.
Key Events · Earnings and Guidance · HURA
-
Cash Position and Runway
Cash and cash equivalents were $1.0 million at June 30, 2026, down from $3.6 million at year-end 2025. Management expects the $50 million Parkview Credit Facility and ATM Program to fund operations into late 2028.
-
Q2 Net Loss and R&D Spend
Net loss was $9.2 million for Q2 2026, with R&D expenses up 34% year-over-year to $6.6 million, driven by IFx-2.0 and TBS-2025 clinical development.
-
CEO 10b5-1 Trading Plan
CEO James A. Bianco adopted a Rule 10b5-1 trading plan on June 4, 2026, providing for potential sale of up to 1,500,000 option shares and other shares over the plan's term.
-
Subsequent Financing Activity
After June 30, 2026, the company borrowed an additional $2.15 million under the Parkview Credit Facility and issued 197,545 shares under the ATM Program at a weighted-average price of $2.35 for gross proceeds of approximately $464,000.
Analysis · HURA · Life Sciences
The Q2 2026 10-Q confirms TuHURA ended June with just $1.0 million in cash, but management expects the $50 million Parkview Credit Facility and ATM Program to fund operations into late 2028. The filing also reveals CEO James Bianco adopted a 10b5-1 plan on June 4, 2026, allowing potential sales of up to 1.5 million option shares, and discloses subsequent draws of $2.15 million on the credit facility and $464,000 in ATM proceeds. The detailed financials show a net loss of $9.2 million for the quarter, with R&D spending up 34% year-over-year as the company advances its IFx-2.0 Phase 3 trial and TBS-2025 program.
At the time of this filing, HURA was trading at $2.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $146.5M. The 52-week trading range was $0.41 to $3.43. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.